Donepezil
|
Better Known as: Aricept
- Marketed By: Eisai & Pfizer
- Major Indication: Alzheimer's Disease
- Drug Class: Acteylcholinesterase Inhibitor
- Date of FDA Approval (Withdrawn): 1996 (2008)
- 2006 Sales: $800 Million
- Why You Should Care: One of the most effective treatments for teh symptoms of Alzheimer's Disease, although no definitive proof exists as to whether to alters the progression of the disease.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| Aceylcholinesterase Inhibitor Pharmacokinetics | ||||||
|---|---|---|---|---|---|---|
| Parameter | Aricept | |||||
| Tmax (hr) | ||||||
| Cmax (ng/ml) | ||||||
| Bioavailability (%) | ||||||
| Protein Binding (%) | ||||||
| T1/2 (hr) | ||||||
| AUC (ng/ml/hr) | ||||||
| IC50 (nM) | ||||||
| Equivalent LDL Reduction Dosage (mg) | ||||||
| Metabolism | ||||||
References